Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00370786

Enrollment

Registered

2006-09-01

Start date

2005-11-30

Completion date

2008-02-29

Last updated

2008-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Choroidal Neovascularization

Keywords

Choroidal neovascularization (CNV), Bevacizumab, Non AMD, High myopia, angioid streaks, Ocular histoplasmosis, Idiopathic

Brief summary

To evaluate the effect of bevacizumab for treatment of non-AMD choroidal neovascularization (CNV); eg:angioid streaks, ocular histoplasmosis, high myopia, idiopathic,etc

Interventions

DRUGbevacizumab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Cases with subfoveal or juxtafoveal CNV due to a non-AMD related cause.

Exclusion criteria

* Evidence of AMD

Design outcomes

Primary

Measure	Time frame
Visual acuity	6 months

Secondary

Measure	Time frame
central macular thickness	6 months
leakage in fluorescein angiography	6 months

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026